Robert Megna, DO
Family Medicine · Ferris, TXNPI 1407872039
Payments from drug & device makers
Across 417 payments — averaging $96.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$28K
- Corcept Therapeutics$4K
- Novartis$2K
- Amarin Pharma, Inc.$883
- Bayer$737
- Boehringer Ingelheim$578
- plus $4K from 31 others
What the payments were for
- Consulting fees$4,27311%
- Speaking & faculty fees$26,11965%
- Travel & lodging$1,5594%
- Food & beverage$8,37221%
- Education$100%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 93 | $28,186 |
| Corcept Therapeutics | 23 | $4,167 |
| Novartis | 20 | $2,258 |
| Amarin Pharma, Inc. | 46 | $883 |
| Bayer | 28 | $737 |
| Boehringer Ingelheim | 30 | $578 |
| Novo Nordisk | 27 | $426 |
| Heartflow, Inc. | 4 | $425 |
| Merck | 22 | $418 |
| AstraZeneca | 17 | $375 |
| Kowa Pharmaceuticals America, Inc. | 15 | $262 |
| Dexcom, Inc. | 13 | $208 |
| Mannkind Corporation | 7 | $165 |
| AbbVie(2 entities) | 9 | $158 |
| Lilly USA, LLC | 10 | $154 |
| Valeritas, Inc. | 10 | $150 |
| Zealand Pharma US, Inc. | 6 | $105 |
| Sanofi-aventis U.S. LLC | 5 | $103 |
| Sumitomo Pharma America, Inc. | 2 | $92 |
| Esperion Therapeutics, Inc. | 5 | $88 |
| Sequel Med Tech, LLC | 2 | $59 |
| Pfizer | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Insulet Corporation | 2 | $31 |
| GSK | 2 | $31 |
| Medicure Pharma Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Abbott | 1 | $25 |
| Nevro Corp. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Edwards Lifesciences | 2 | $20 |
| Seqirus USA Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Althera Pharmaceuticals LLC | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,392 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 148 | $178,030 |
| Repatha SureclickEvolocumab | 138 | $152,685 |
| OzempicSemaglutide | 135 | $146,341 |
| VascepaIcosapent Ethyl | 123 | $99,229 |
| MounjaroTirzepatide | 77 | $94,568 |
| EliquisApixaban | 80 | $91,688 |
| FarxigaDapagliflozin Propanediol | 66 | $81,439 |
| XareltoRivaroxaban | 74 | $76,319 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $59,497 |
| KerendiaFinerenone | 36 | $44,045 |
| EntrestoSacubitril/Valsartan | 27 | $42,563 |
| Praluent PenAlirocumab | 27 | $31,976 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $29,485 |
| JanuviaSitagliptin Phosphate | 22 | $23,297 |
| TrulicityDulaglutide | 11 | $21,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $578 | $209,795200 claims |
| Novo NordiskOzempic | $426 | $146,341135 claims |
| Lilly USA, LLCMounjaro, Trulicity | $154 | $115,98488 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $375 | $98,89299 claims |
| PfizerEliquis | $48 | $91,68880 claims |
| BayerKerendia | $737 | $44,04536 claims |
| NovartisEntresto | $2,258 | $42,56327 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $31 | $28,84638 claims |
| MerckJanuvia | $418 | $23,29722 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $262 | $10,51818 claims |
| AbbVieSynthroid | $158 | $4,80765 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Ferris
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.